Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gap filled 6s 7s next top
With the type of news this should have been above 5 not sure whats wrong here?
3.20 gap must fill now
We get some 5s I'm backing up the truck
Was a good trade but it's been done since 7s
Weeeeeeeeeeeee
Looking good
Bounced off the low 3s time to load
Maybe an A B C ... 2.17 might coming
Great day here! $OMER
Breaking out!
Wow! Thanks for sharing. I can't believe with all that going for it and the price is so beaten down.
So what happens to OMER…a public company with tons of cash and no business operations?
Bahhh Bahhh
gonna do this all day long
another round for the apes Lets GO !!
Glad I'm just a robot no emotions needed
Fk with BB My new addiction
IN now I'm gonna tick flip this POS to death
Trying for the baseline
no holds barred..
Shorts feeling the heat!!!!! >
OMER > That is a sweet revenue deal. OMER heading to $20.00+
$125 million upfront payment and $200 million on achievement of commercial milestone
Royalties of 50% on U.S. net sales until the earlier of either January 1, 2025 or payment of the $200-million milestone, after which royalties adjust to 30% of U.S. net sales
Royalties of 15% on ex-U.S. net sales
OMIDRIA to become a premier product in Rayner’s ophthalmology franchise
In addition to acquiring the OMIDRIA commercial organization, including the current OMIDRIA sales force, Rayner plans to further expand its U.S. and ex-U.S. sales forces
Here are the 5!
Very interesting if it goes under!
I would be tempted to open the position now!
Someone says 5 ... will it get there?
I would like to enter but of course they spend a lot on research and development... and for sell
Buying opportunity???
I created a page on my site talking about OMER. Let me know if I am missing any nuggets. Thanks.
https://frugalnorwegian.com/omer
Summary: This company is a prime candidate for a buyout if FDA approval is given.
If one is worried about fda's delay, Check out @alanrobertross message on StockTwits http://stocktwits.com/alanrobertross/message/333077805
Tute ownership up to 78% been hovering around 50% for years. 20% short
Not new news but I like the smart reporting style:
Omeros's Biologics License Application for Blood Vessel Damage Treatment Candidate Accepted for Priority Review by FDA
1/19/21, 8:06 AM
10:06 AM EST, 01/19/2021 (MT Newswires) -- Omeros (OMER) said Tuesday its biologics license application for narsoplimab, a potential treatment for transplant-associated thrombotic microangiopathy, has been accepted for priority review by the US Food and Drug Administration.
Thrombotic microangiopathy is characterized by a pattern of damage in the small blood vessels.
The FDA has set the Prescription Drug User Fee Act action date on July 17.
Have you looked at NLST? Short story:
*google signed a NDA with NLST to use their seminal technology
*google was bad even lied to court
*they lost their appeal
*google let date to file with scotus pass
*now one way or another they must pay
*one way to pay--google's case and settlement with ADT(eye opening)
*another way to pay-- Centripetal v Cisco (cisco was bad for 3 yrs
google is on the hook for 11 yrs)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160597164
*estimate to file to lift stay Q1 2021
*bought dips as low as .48 keep adding
*yahoo board and ihub board are bullish
lots of speculation but also good info.
*there are active cases with other companies Sk-hynic recently lost
on 2 parts of patent 907
*scheduled markman for infringement of (NLST)patents 218 and 595 3/9/2021
trial, if defendants choose, 12/2021
*it is a popping year for NLST they have been chasing google in court for 11 yrs, google will have to settle.
Followers
|
37
|
Posters
|
|
Posts (Today)
|
0
|